Clinical trials: Depression NOS
Major Depressive Disorder, Treatment Resistant Depression
Open-Label Safety Study of AXS-05 in Subjects With Depression
An open-label, long-term, safety study of AXS-05 in patients with major depressive disorder (MDD), including treatment resistant depression.
- Conditions
- Major Depressive Disorder, Treatment Resistant Depression, Depression
- Trial name
- NCT04039022
- Testing
- AXS-05 (dextromethorphan and bupropion) oral tablets
- Where
- 51 sites in United States
- Volunteers
- 876 people
- Sponsor
- Axsome Therapeutics, Inc.
Depression
Reclaim Deep Brain Stimulation Clinical Study for Treatment-Resistant Depression
Medtronic, Inc. sponsored an investigational study of the Reclaim™ Deep Brain Stimulation (DBS) System in people that have treatment-resistant depression.
- Trial name
- NCT00837486
- Testing
- Reclaim™ DBS System
- Where
- 5 sites in United States
- Volunteers
- 30 people
- Sponsor
- MedtronicNeuro
Major Depressive Disorder
Study to Assess the Efficacy and Safety of NBI-1065845 in Adults With Major Depressive Disorder (MDD)
The purpose of this study is to evaluate the efficacy of NBI-1065845 compared with placebo in participants with MDD on improving symptoms of depression.
- Trial name
- SAVITRI (NCT05203341)
- Testing
- NBI-1065845
- Where
- 41 sites in United States, Bulgaria and 4 more
- Volunteers
- 183 people
- Sponsor
- Neurocrine Biosciences
Multiple Sclerosis
Depression and Fatigue in MS Patients Treated With Betaferon.
This study aims to evaluate the occurence and severity of fatigue and depression in multiple sclerosis patients and the impact of Betaferon treatment on symptoms alterations.
- Trial name
- FADO (NCT01354665)
- Testing
- Interferon beta-1b (Betaferon, BAY86-5046)
- Where
- Poland
- Volunteers
- 567 people
- Sponsor
- Bayer
Depression, Anxiety
Clinical Study Evaluating Effects of Pharmacogenetic-guided vs Standard-of-Care Treatment on Depression and/or Anxiety
A prospective, multi-center, randomized, subject and outcome evaluator blind , parallel-group study evaluating the effect of pharmacogenetic-guided versus standard of care treatment for subjects diagnosed with depression and/or…
- Trial name
- NCT02878928
- Testing
- IDgenetix Neuropsychiatric Test Panel
- Where
- 17 sites in United States
- Volunteers
- 579 people
- Sponsor
- AltheaDx
Bipolar II Disorder
Phase 2 Clinical Trial of GH001 in Bipolar II Disorder
This study is a multicenter, open-label, single-arm Phase 2 clinical trial. Approximately 15 participants with clinically diagnosed bipolar disorder (BD) type II and experiencing a current episode of depression will be included…
- Trial name
- NCT05839509
- Testing
- GH001
- Where
- 7 sites in Germany, Netherlands and 1 more
- Volunteers
- 6 people
- Sponsor
- GH Research Ireland Limited
Depressive Disorder, Major, Major Depressive Disorder (MDD)
Patient Tolerability Study of GSK163090
The purpose of this study is to determine the safety and tolerability of a new drug, GSK163090, which is being developed for the treatment of depression and anxiety disorders.
- Trial name
- NCT00559299
- Testing
- GSK163090
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- GlaxoSmithKline
Major Depressive Disorder
A Closed-loop Assessment and Treatment Platform for Unipolar Depression and Anxiety
Specific Aim 1: Finalize development of the closed-loop strategy in the MMT application. Specific Aim 2: Evaluate the acceptability and feasibility of the MMT application with the target population to prepare for a large-scale…
- Trial name
- NCT02948036
- Testing
- Mobile-device, plasticity-based adaptive cognitive treatment
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- Posit Science Corporation
Depressive Episodes, Bipolar I Depression
A Clinical Trial to Determine the Long-term Safety and Tolerability of an Investigational Drug in People With Major Depressive Episode Associated With Bipolar I Disorder (Bipolar I Depression).
This is a clinical trial to determine the long-term safety and tolerability of an investigational drug in people with Major Depressive Episode Associated with Bipolar I Disorder (Bipolar I Depression).
- Trial name
- NCT05227209
- Testing
- SEP-4199 CR
- Where
- 69 sites in United States, Bulgaria and 1 more
- Volunteers
- 64 people
- Sponsor
- Sumitomo Pharma America, Inc.
Major Depressive Disorder
Safety and Efficacy of Vilazodone in Major Depressive Disorder
The purpose of this study was to evaluate the efficacy, safety, and tolerability of 2 fixed dose levels of vilazodone compared to placebo in patients with major depressive disorder.
- Trial name
- VLZ-MD-01 (NCT01473381)
- Testing
- Vilazodone, Citalopram
- Where
- 54 sites in United States
- Volunteers
- 1,162 people
- Sponsor
- Forest Laboratories
Depression, Major Depressive Disorder
Effect of SSRIs on Response to Psilocybin Therapy
This study is an open-label, single-arm, within-subjects design in individuals with mild-moderate Major Depressive Disorder (MDD). All participants will receive a single dose of 25mg of psilocybin in a therapeutic setting.
- Conditions
- Depression, Major Depressive Disorder, Mild Depression, Moderate Depression
- Trial name
- NCT05594667
- Testing
- Psilocybin
- Where
- Canada
- Sponsor
- Cybin Therapeutics Inc.
Depression
Single Dose Study of BMS-820836
The purpose of this study is to determine the safety and tolerability of BMS-820836 after single doses
- Trial name
- NCT00964912
- Testing
- BMS-820836
- Where
- Canada
- Volunteers
- 68 people, healthy volunteers welcome
- Sponsor
- Bristol-Myers Squibb
Major Depressive Disorder
Software Treatments for Actively Reducing Severity of Cognitive Deficits in MDD (STARS-MDD)
The purpose of this study is to evaluate the effects of videogame-like digital therapies as adjunct therapy to antidepressant medications on cognitive deficits associated with major depressive disorder.
- Trial name
- NCT03310281
- Testing
- HOLD: Videogame
- Where
- 4 sites in United States
- Volunteers
- 84 people
- Sponsor
- Akili Interactive Labs, Inc.
Treatment Resistant Major Depressive Disorder
Repeated Intranasal Esketamine Plus Almond Therapy in Patients With Treatment Resistant Depression
To examine the efficacy of Almond Therapy compared to Treatment as Usual when used in addition to an approved version of intranasal esketamine.
- Trial name
- ZYL-730-01 (NCT05323019)
- Testing
- Psychotherapy, Treatment as Usual, Intranasal Ketamine (esketamine)
- Where
- Canada
- Volunteers
- 6 people
- Sponsor
- Zylorion Health
Bipolar Depression
Study to Evaluate the Effects of Switching Different Strength Forms of FK949E in Bipolar Disorder Patients With Major Depressive Episodes
The purpose of this study was to evaluate the efficacy, safety, and pharmacokinetics of switching FK949E (sustained-release quetiapine) 50-mg and 150-mg tablets to the other tablet at the equivalent total daily dose in bipolar…
- Trial name
- NCT02362412
- Testing
- FK949E
- Where
- 7 sites in Japan
- Volunteers
- 22 people
- Sponsor
- Astellas Pharma Inc
Chronic Kidney Disease Stage 5
Quality of Life and Depression in Dialysis Patients
The aim of this study is to evaluate quality of life (QOL) and depression in peritoneal dialysis patients compare to hemodialysis patients and assess hydration effect on QOL and depression over time.
- Trial name
- QOLD (NCT01668628)
- Where
- South Korea
- Volunteers
- 1,068 people
- Sponsor
- Fresenius Medical Care Korea
Postpartum Depression
Expanded Access Protocol of ZULRESSO™ (Brexanolone) Injection for Adult Patients With Postpartum Depression
This is an expanded access program intended to provide access to ZULRESSO™ (brexanolone) injection for the treatment of a limited number of eligible women with postpartum depression during the period prior to commercial…
- Trial name
- NCT03924492
- Testing
- ZULRESSO (brexanolone) injection
- Sponsor
- Supernus Pharmaceuticals, Inc.
Bipolar Disorder
Bipolar Disorder Study for Men and Women
A Placebo Controlled Study Evaluating Efficacy and Safety of Medication in Patients with Bipolar Disorder
- Trial name
- NCT00056277
- Testing
- lamotrigine
- Where
- 20 sites in United States
- Volunteers
- 150 people
- Sponsor
- GlaxoSmithKline
Depression - Major Depressive Disorder, Anxiety
AcceXible Speech-Based Screening for Depression and Anxiety in University Students (BUAP, Mexico)
Major depressive disorder (MDD) and anxiety are increasingly prevalent among university student populations, yet early detection remains reliant on psychometric instruments tied to diagnostic criteria (e.g., PHQ-9, GAD).
- Trial name
- NCT07553130
- Testing
- AcceXible
- Where
- Mexico
- Volunteers
- 785 people, healthy volunteers welcome
- Sponsor
- Accexible
Anxiety, Depression
A Randomized-Controlled Trial to Investigate the Effect of a Novel Music Therapy Application to Reduce Anxiety and Stress
This virtual, open-label, three-group, randomized-controlled trial will last six weeks. Participants will be allocated into three groups; the Intervention Group, Spotify Group, and Control Group.
- Conditions
- Anxiety, Depression, Stress
- Trial name
- NCT06021821
- Testing
- SoundMind App, Spotify Playlist
- Where
- United States
- Volunteers
- 75 people, healthy volunteers welcome
- Sponsor
- SoundMind